10967/276 - QDB Compounds

QsarDB Repository

Zukic, S.; Ivanova, L.; Zusinaite, E.; Merits, A.; Maran, U. Discovery of a Novel Phthalazine-Based VEGFR-2 Inhibitor by Machine Learning Analysis of Diverse Chemical Space with Favorable Pharmacophores and Its Evaluation in Glioblastoma Cell Lines. Results in Chemistry, Under revision

216 compounds | Property pIC50: Negative logarithm of half-maximal inhibitory concentration [-log(uM)]

IDNamepIC50RefDetails
1Compound 1 i7.1[1]View
2Compound 2 i6.72[1]View
3Compound 3 i7.15[1]View
4Compound 4 i7[1]View
5Compound 5 i6.57[1]View
6Compound 6 i6.44[1]View
7Compound 7 i6.67[2]View
8Compound 8 i6.89[2]View
9Compound 9 i6.92[2]View
10Compound 10 i6.6[2]View
11Compound 11 i6.8[2]View
12Compound 12 i6.72[2]View
13Compound 13 i6.82[2]View
14Compound 14 i6.68[2]View
15Compound 15 i6.72[2]View
16Compound 16 i6.52[2]View
17Compound 17 i9.34[3]View
18Compound 18 i9.03[3]View
19Compound 19 i9.06[3]View
20Compound 20 i9.16[3]View
21Compound 21 i9.14[3]View
22Compound 22 i9.46[3]View
23Compound 23 i9.16[3]View
24Compound 24 i9.36[3]View
25Compound 25 i9.64[3]View
26Compound 26 i9.07[3]View
27Compound 27 i9.07[3]View
28Compound 28 i9.26[3]View
29Compound 29 i9.2[3]View
30Compound 30 i9.24[3]View
31Compound 31 i9.34[3]View
32Compound 32 i9.27[3]View
33Compound 33 i9.25[3]View
34Compound 34 i9.13[3]View
35Compound 35 i9.08[3]View
36Compound 36 i9.17[3]View
37Compound 37 i9.35[3]View
38Compound 38 i9.19[3]View
39Compound 39 i9.19[3]View
40Compound 40 i9.35[3]View
41Compound 41 i9.34[3]View
42Compound 42 i9.26[3]View
43Compound 43 i9.19[3]View
44Compound 44 i9.27[3]View
45Compound 45 i9.11[3]View
46Compound 46 i9.47[3]View
47Compound 47 i9.6[3]View
48Compound 48 i9.72[3]View
49Compound 49 i9.26[3]View
50Compound 50 i9.36[3]View
51Compound 51 i6.18[4]View
52Compound 52 i6.44[4]View
53Compound 53 i6.72[5]View
54Compound 54 i6.72[5]View
55Compound 55 i6.54[5]View
56Compound 56 i6.89[5]View
57Compound 57 i6.89[5]View
58Compound 58 i6.92[5]View
59Compound 59 i6.6[5]View
60Compound 60 i6.48[5]View
61Compound 61 i6.85[5]View
62Compound 62 i6.72[5]View
63Compound 63 i6.8[5]View
64Compound 64 i6.6[5]View
65Compound 65 i5.98[6]View
66Compound 66 i5.99[6]View
67Compound 67 i5.87[6]View
68Compound 68 i6.12[6]View
69Compound 69 i7.49[7]View
70Compound 70 i7.65[7]View
71Compound 71 i7.94[7]View
72Compound 72 i7.66[7]View
73Compound 73 i7.66[7]View
74Compound 74 i7.97[7]View
75Compound 75 i8.38[7]View
76Compound 76 i8.01[7]View
77Compound 77 i7.53[7]View
78Compound 78 i8.06[7]View
79Compound 79 i7.86[7]View
80Compound 80 i7.8[7]View
81Compound 81 i7.56[7]View
82Compound 82 i8.31[7]View
83Compound 83 i7.41[7]View
84Compound 84 i7.93[7]View
85Compound 85 i8.21[7]View
86Compound 86 i7.97[7]View
87Compound 87 i8.29[7]View
88Compound 88 i7.62[7]View
89Compound 89 i6.03[8]View
90Compound 90 i6.04[8]View
91Compound 91 i6.05[8]View
92Compound 92 i6.34[8]View
93Compound 93 i6.36[8]View
94Compound 94 i6.36[8]View
95Compound 95 i6.77[8]View
96Compound 96 i6.82[8]View
97Compound 97 i7.1[8]View
98Compound 98 i6.85[8]View
99Compound 99 i6.96[8]View
100Compound 100 i7.1[8]View
101Compound 101 i7.22[9]View
102Compound 102 i6.89[9]View
103Compound 103 i6.64[9]View
104Compound 104 i7.2[9]View
105Compound 105 i6.86[10]View
106Compound 106 i6.73[10]View
107Compound 107 i7.01[10]View
108Compound 108 i7.16[10]View
109Compound 109 i7.07[10]View
110Compound 110 i7.66[11]View
111Compound 111 i7.1[11]View
112Compound 112 i7.81[11]View
113Compound 113 i7.64[11]View
114Compound 114 i6.6[12]View
115Compound 115 i6.7[12]View
116Compound 116 i6.21[12]View
117Compound 117 i6.19[12]View
118Compound 118 i6.7[12]View
119Compound 119 i6.92[12]View
120Compound 120 i6.89[12]View
121Compound 121 i6.72[12]View
122Compound 122 i6.92[12]View
123Compound 123 i6.17[13]View
124Compound 124 i6.21[13]View
125Compound 125 i6.47[13]View
126Compound 126 i6.54[13]View
127Compound 127 i6.55[13]View
128Compound 128 i6.17[13]View
129Compound 129 i6.2[13]View
130Compound 130 i6.14[13]View
131Compound 131 i6.21[13]View
132Compound 132 i6.31[13]View
133Compound 133 i6.49[13]View
134Compound 134 i6.59[13]View
135Compound 135 i6.24[13]View
136Compound 136 i6.15[14]View
137Compound 137 i6.14[14]View
138Compound 138 i6.06[14]View
139Compound 139 i6.06[14]View
140Compound 140 i6.22[14]View
141Compound 141 i6.22[14]View
142Compound 142 i6.44[14]View
143Compound 143 i6.05[14]View
144Compound 144 i6.96[14]View
145Compound 145 i6.59[14]View
146Compound 146 i6.77[14]View
147Compound 147 i6.85[14]View
148Compound 148 i7[14]View
149Compound 149 i7.1[14]View
150Compound 150 i6.64[14]View
151Compound 151 i6.09[15]View
152Compound 152 i6.2[15]View
153Compound 153 i6.2[15]View
154Compound 154 i6.06[15]View
155Compound 155 i6.19[15]View
156Compound 156 i6.36[15]View
157Compound 157 i6.19[15]View
158Compound 158 i6.08[15]View
159Compound 159 i6.66[15]View
160Compound 160 i6.36[15]View
161Compound 161 i6.96[15]View
162Compound 162 i6.4[15]View
163Compound 163 i6.89[15]View
164Compound 164 i6.17[15]View
165Compound 165 i6.77[15]View
166Compound 166 i6.55[15]View
167Compound 167 i6.57[16]View
168Compound 168 i6.64[16]View
169Compound 169 i6.64[16]View
170Compound 170 i6.7[16]View
171Compound 171 i6.72[16]View
172Compound 172 i6.77[16]View
173Compound 173 i6.64[16]View
174Compound 174 i6.66[16]View
175Compound 175 i6.7[16]View
176Compound 176 i6.74[16]View
177Compound 177 i6.74[16]View
178Compound 178 i6.77[16]View
179Compound 179 i5.02[17]View
180Compound 180 i5.05[17]View
181Compound 181 i5.17[17]View
182Compound 182 i5.52[17]View
183Compound 183 i6.85[17]View
184Compound 184 i6.74[17]View
185Compound 185 i6.46[17]View
186Compound 186 i6.62[17]View
187Compound 187 i6.68[17]View
188Compound 188 i5.43[17]View
189Compound 189 i5.7[17]View
190Compound 190 i5.81[17]View
191Compound 191 i6.13[18]View
192Compound 192 i6.14[18]View
193Compound 193 i6.15[18]View
194Compound 194 i6.17[18]View
195Compound 195 i6.17[18]View
196Compound 196 i6.4[18]View
197Compound 197 i6.55[18]View
198Compound 198 i6.6[18]View
199Compound 199 i6.66[18]View
200Compound 200 i7[18]View
201Compound 201 i5.84[19]View
202Compound 202 i5.88[19]View
203Compound 203 i5.93[19]View
204Compound 204 i5.92[19]View
205Compound 205 i5.81[19]View
206Compound 206 i5.87[19]View
207Compound 207 i5.89[19]View
208Compound 208 i6.96[19]View
209Compound 209 i6.51[19]View
210Compound 210 i6.04[19]View
211Compound 211 i6.14[19]View
212Compound 212 i7.21[20]View
213Compound 213 i7.01[20]View
214Compound 214 i7.27[20]View
215Compound 215 i7.21[20]View
216Compound 216 i7.08[20]View

Bibliography

  1. El-Helby, A.-G. A.; Sakr, H.; Eissa, I. H. a. A., H.; Al-Karmalawy, A. A.; El-Adl, K. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2019, 352, e1900113. https://doi.org/10.1002/ardp.201900113

  2. El-Helby, A.-G. A.; Sakr, H.; Eissa, I. H. a. A.-K., A. A.; El-Adl, K. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations. Arch. Pharm. (Weinheim) 2019, 352, e1900178. https://doi.org/10.1002/ardp.201900178

  3. AbdelHaleem, A.; Mansour, A. O.; AbdelKader, M. a. A., R. K. Selective VEGFR-2 inhibitors: Synthesis of pyridine derivatives, cytotoxicity and apoptosis induction profiling. Bioorg. Chem. 2020, 103, 104222. https://doi.org/10.1016/j.bioorg.2020.104222

  4. Ahmed, E. Y.; Abdel Latif, N. A.; El-Mansy, M. F. a. E., W. S.; Abdelhafez, O. M. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Bioorg. Med. Chem. 2020, 28, 115328. https://doi.org/10.1016/j.bmc.2020.115328

  5. Saleh, N. M.; Abdel-Rahman, A. A.-H.; Omar, A. M. a. K., M. M.; El-Adl, K. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking. Arch. Pharm. (Weinheim) 2021, 354, e2100085. https://doi.org/10.1002/ardp.202100085

  6. El-Adl, K.; Sakr, H. M.; Yousef, R. G.; Mehany, A. B. M.; Abulkhair, H. S.; Eissa, I. H. New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies. Arch. Pharm. (Weinheim) 2022, 355, e2200048. https://doi.org//10.1002/ardp.202200048

  7. Alanazi, M. M.; Eissa, I. H.; Alsaif, N. A. a. O., A. J.; Alanazi, W. A.; Alasmari, A. F. a. A., H.; Elkady, H.; Elwan, A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J. Enzyme Inhib. Med. Chem. 2021, 36, 1760–1782. https://doi.org/10.1080/14756366.2021.1956488

  8. Abdelgawad, M. A.; El-Adl, K.; El-Hddad, S. S. A.; Elhady, M. M.; Saleh, N. M. a. K., M. M.; Khedr, F.; Alswah, M. a. N., A. A.; Ghoneim, M. M.; Abd El-Sattar, N. E. A. Design, molecular docking, synthesis, anticancer and anti-hyperglycemic assessments of thiazolidine-2,4-diones bearing sulfonylthiourea moieties as potent VEGFR-2 inhibitors and PPARy agonists. Pharmaceuticals (Basel) 2022, 15, 226. https://doi.org/10.3390/ph15020226

  9. Elkaeed, E. B.; Yousef, R. G.; Khalifa, M. M. a. I., A.; Mehany, A. B. M.; Gobaara, I. M. M. a. A., B. A.; Eldehna, W. M.; Metwaly, A. M. a. E., I. H.; El-Zahabi, M. A. Discovery of new VEGFR-2 inhibitors: Design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies. Molecules 2022, 27, 6203. https://doi.org/10.3390/molecules27196203

  10. Elkaeed, E. B.; Taghour, M. S.; Mahdy, H. A. a. E., W. M.; El-Deeb, N. M.; Kenawy, A. M.; A Alsfouk, B.; Dahab, M. A.; Metwaly, A. M. a. E., I. H.; El-Zahabi, M. A. New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. J. Enzyme Inhib. Med. Chem. 2022, 37, 2191–2205. https://doi.org/10.1080/14756366.2022.2110869

  11. Yousef, R. G.; Ibrahim, A.; Khalifa, M. M. a. E., W. M.; Gobaara, I. M. M.; Mehany, A. B. M. a. E., E. B.; Alsfouk, A. A.; Metwaly, A. M. a. E., I. H. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J. Enzyme Inhib. Med. Chem. 2022, 37, 1389–1403. https://doi.org/10.1080/14756366.2022.2070744

  12. El-Adl, K.; El-Helby, A.-G. A.; Sakr, H. a. E.-H., S. S. A. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2020, 353, e2000068. https://doi.org/10.1002/ardp.202000068

  13. El-Adl, K.; Sakr, H.; El-Hddad, S. S. A. a. E.-H., A.-G. A.; Nasser, M.; Abulkhair, H. S. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2021, 354, e2000491. https://doi.org/10.1002/ardp.202000491

  14. El-Adl, K.; Ibrahim, M. K.; Khedr, F. a. A., H. S.; Eissa, I. H. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2022, 355, e2100278. https://doi.org/10.1002/ardp.202100278

  15. Khedr, F.; Ibrahim, M.-K.; Eissa, I. H. a. A., H. S.; El-Adl, K. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Arch. Pharm. (Weinheim) 2021, 354, e2100201. https://doi.org/10.1002/ardp.202100201

  16. El-Adl, K.; El-Helby, A.-G. A.; Sakr, H. a. A., R. R.; Mahdy, H. A.; Nasser, M. a. A., H. S.; El-Hddad, S. S. A. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2021, 354, e2000279. https://doi.org/10.1002/ardp.202000279

  17. El-Adl, K.; Ibrahim, M.-K.; Khedr, F. a. A., H. S.; Eissa, I. H. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies. Arch. Pharm. (Weinheim) 2021, 354, e2000219. https://doi.org/10.1002/ardp.202000219

  18. El-Adl, K.; El-Helby, A.-G. A.; Sakr, H. a. E., I. H.; El-Hddad, S. S. A.; M I A Shoman, F. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme. Bioorg. Chem. 2020, 102, 104059. https://doi.org/j.bioorg.2020.104059

  19. El-Helby, A.-G. A.; Ayyad, R. R. A.; Sakr, H. a. E.-A., K.; Ali, M. M.; Khedr, F. Design, synthesis, molecular docking, and anticancer activity of phthalazine derivatives as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2017, 350, 1700240. https://doi.org/10.1002/ardp.201700240

  20. Abdallah, A. E.; Eissa, S. I.; Al Ward, M. M. S.; Mabrouk, R. R.; Mehany, A. B. M. a. E.-Z., M. A. Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation. Bioorg. Chem. 2021, 109, 104695. https://doi.org/10.1016/j.bioorg.2021.104695